Thalia Therapeutics raises £2.75 million alongside Sanmirna acquisition
The placing and subscription funds RNA-therapy development, including completion of the miRisten Phase 1 trial.
Thalia Therapeutics announced a £2.75 million placing and subscription on June 24, 2026, alongside its proposed acquisition of Sanmirna Therapeutics. Investors subscribed for new shares at 0.6 pence each.
The fundraise included £1,292,500 from directors and Sanmirna’s vendors, with Premier Miton among the other disclosed investors. Director subscriptions accounted for £1,117,500.
Thalia allocated £1 million to completing the miRisten Phase 1 trial, £750,000 to its cardiovascular programme and £1 million to working capital, further research and transaction costs.
The financing was separate from the shares and convertible loan note issued as acquisition consideration. A second fundraising tranche required shareholder approval; the company subsequently confirmed completion in July.
Use of funds
Complete miRisten Phase 1 trial
Advance cardiovascular siRNA programme
Working capital, R&D and transaction costs